US drug approvals
1 approvals with a product on the US market
- Vyndamax NDA212161 · approved 3 May 2019
Source: Drugs@FDA, Approvals (NDA, ANDA, BLA) held, with a product sold now; newest shown. Retrieved 13 Nov 2026.
- 0Reports naming them
- 1Markets in public records
- 0Regions & countries
- See reportsGrowth in full reports
Free public data on Foldrx Pharmaceuticals
From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.
See them on openFDA (opens in a new tab)
Markets where public records show them
Markets we cover where free public records show Foldrx Pharmaceuticals: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.
Topics
The topics of the markets Foldrx Pharmaceuticals is in.
From our blog
Stories on the topics Foldrx Pharmaceuticals works in.
Omega-3: Heart, Brain and the Evidence Debate
Omega-3 supplements are hugely popular. Big trials give mixed answers on whether they protect the heart.
Read
Brain Cancer Diagnosis: Imaging and New Biomarkers
About 321,000 people were diagnosed with brain and nervous system tumours in 2022, and about 248,000 died…
Read
Alzheimer's Diagnosis: Blood Tests and Earlier Answers
57 million people live with dementia. In May 2025 the US FDA cleared the first blood test used to help…
Read